Gujarat kidney and super speciality Limited has completed the acquisition of Parekhs Hospital Private Limited as a wholly owned subsidiary on March 22, 2026. The company informed the stock exchanges about this strategic move under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition Details

The acquisition was executed through cash consideration, marking a significant expansion in the healthcare sector for Gujarat Kidney and Super Speciality Limited.

Target Company Profile

Parekhs Hospital Private Limited, incorporated on January 13, 2006, operates as a medical and healthcare service provider with its registered office in Ahmedabad, Gujarat. The company has established itself in the healthcare sector over nearly two decades of operations.

Financial Structure

Revenue Performance

Parekhs Hospital has demonstrated consistent revenue generation over the past three financial years, showing resilience in the healthcare services market.

Strategic Rationale

The acquisition aligns with Gujarat Kidney and Super Speciality Limited's expansion strategy in the healthcare sector. According to the company's disclosure, the acquisition of 100% stake in the target company will help strengthen the company's presence in the healthcare sector and diversify its business portfolio.

The transaction does not fall within related party transactions, and no promoter or promoter group companies have any interest in the acquired entity. The acquisition required no governmental or regulatory approvals, facilitating a smooth transaction process.

Corporate Compliance

The acquisition was disclosed in accordance with regulatory requirements, with Company Secretary and Compliance Officer Niki Tiwari (Membership No. 45550) signing the disclosure document. The information has also been uploaded on the company's website at www.gujaratsuperspecialityhospital.com for stakeholder access.

Gujarat kidney and super speciality Limited has completed payment of regulatory fines totaling ₹6,60,800 to both major Indian stock exchanges for failing to comply with mandatory financial reporting requirements. The healthcare company paid the penalties on March 20, 2026, following penalty notices received from NSE and BSE on March 17, 2026.

Penalty Payment Details

The company has settled the fines imposed by both stock exchanges for violating Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The penalties were paid via RTGS at 3:15 PM on March 20, 2026.

Regulatory Violation and Compliance

The penalty stems from the company's failure to submit financial results for the quarter ended September 30, 2025 within the prescribed timeline under Regulation 33 of LODR 2015. Both exchanges imposed identical fines for non-submission of quarterly financial results within the stipulated period.

The company has now fulfilled its payment obligations within the timelines prescribed by both stock exchanges, ensuring compliance with the penalty orders.

Company's Official Communication

Company Secretary and Compliance Officer Niki Tiwari formally communicated the penalty payment to both stock exchanges on March 21, 2026, under Regulation 30 of the listing regulations. The communication was digitally signed and submitted with proper documentation as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Financial Impact Assessment

According to the company's official disclosure, since the total penalty amount of ₹6,60,800 has been paid in full, no further payments are required. The company has stated that there is no additional financial impact expected from this regulatory action, and the penalty settlement closes the matter with both exchanges.

The healthcare company continues its operations without any material impact on its financial, operational, or other business activities following the penalty payment completion.